Business
FDA website posts Duaklir NDA approval
FDA website posts Duaklir NDA approval.
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 5475U Circassia Pharmaceuticals Plc 29 March 2019 \n\nCircassia Notes FDA Website Posting of Duaklir® in Approvals Section \n \nOxford, UK - 29 March 2019: Circassia Pharmaceuticals plc (\"Circassia\" or \"the Company\"; LSE: CIR), notes the US Food and Drug Administration (FDA) website includes Duaklir® as an FDA approved drug product with an action date of 29 March 2019. Circassia and AstraZeneca are seeking confirmation from FDA and intend to update the market as soon as possible with further details. \n \n \nContacts\nCircassia\nSteve Harris, Chief Executive Officer Tel: +44 (0) 1865 405 560\nJulien Cotta, Chief Financial Officer\nRob Budge, Corporate Communications\n \nPeel Hunt (Nominated Adviser and Joint Broker)\nJames Steel / Dr Christopher Golden Tel: +44 (0) 20 7418 8900\n \nNumis Securities (Joint Broker)\nJames Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000\n \nFTI Consulting\nSimon Conway / George Kendrick &nb...